Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Questions and Answers about the ACCORD Trial — Updated June 6, 2008

Effects of Intensive Glucose Lowering in Type 2 Diabetes Announcements — June 6, 2008

• New Release: ACCORD Clinical Trial Publishes Results—
  A Therapeutic Strategy Targeting Blood Sugar to Near-Normal Levels Does Not Reduce Cardiovascular Events But Increases Mortality in Persons with Diabetes at High Risk

• NEJM: Effects of Intensive Glucose Lowering in Type 2 Diabetes

NEJM Editorials and Perspective:

• Intensive Glycemic Control in the ACCORD and ADVANCE Trials, Robert G. Dluhy, M.D., and Graham T. McMahon, M.D., M.M.Sc.
• Glycemic Targets and Cardiovascular Disease, William T. Cefalu, M.D.
• Redefining Quality - Implications of Recent Clinical Trials, Harlan M. Krumholz, M.D., and Thomas H. Lee, M.D.

ACCORD Blood Sugar Strategy Announcement — February 6, 2008

• Sample Letter To Participants

• News Conference

• News Release

• Prepared Remarks, PDF file, 540 K

  • Elizabeth G. Nabel, MD
  • William T. Friedewald, MD
  • Hertzel C. Gerstein, MD, MSc FRCPC
  • Judith Fradkin, MD

• The Full News Conference

  • Audio, WAV file, 56.7 MB
  • Transcript, PDF file, 132 K

ACCORD Study Web Site

• List of ACCORD Clinical Center Networks and Network Sites

Last updated: February 13, 2008